Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade

por Kofla, G., Radecke, C., Frentsch, M., Walther, W., Stintzing, S., Riess, H., Bullinger, L., Na, I-K.
Publicado 2022

P1613: SINGLE-CELL ANALYSIS FOLLOWING SARS-COV-2 MRNA VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

por Tranter, E., Obermayer-Wasserscheid, B., Hütter-Krönke, M.-L., Junkuhn, C., Blau, I.-W., Vuong, G. L., Bullinger, L., Na, I.-K.
Publicado 2022

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation

por Thiel, V N, Giaimo, B D, Schwarz, P, Soller, K, Vas, V, Bartkuhn, M, Blätte, T J, Döhner, K, Bullinger, L, Borggrefe, T, Geiger, H, Oswald, F
Publicado 2017

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information

por Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R., Kleger, A., Bullinger, L., Seufferlein, T., Berger, A. W.
Publicado 2019

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma – a single-centre retrospective analysis

por Brandes, F., Striefler, J. K., Dörr, A., Schmiester, M., Märdian, S., Koulaxouzidis, G., Kaul, D., Behzadi, A., Thuss-Patience, P., Ahn, J., Pelzer, U., Bullinger, L., Flörcken, A.
Publicado 2021

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT

por Bohl, S, von Harsdorf, S, Mulaw, M, Hofmann, S, Babiak, A, Maier, C P, Schnell, J, Hütter-Krönke, L-M, Scholl, K, Wais, V, Schlenk, R F, Bullinger, L, Ringhoffer, M, Döhner, H, Bunjes, D, Bommer, M, Kuchenbauer, F
Publicado 2016

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial

por Hoyer, K., Hablesreiter, R., Inoue, Y., Yoshida, K., Briest, F., Christen, F., Kakiuchi, N., Yoshizato, T., Shiozawa, Y., Shiraishi, Y., Striefler, J.K., Bischoff, S., Lohneis, P., Putter, H., Blau, O., Keilholz, U., Bullinger, L., Pelzer, U., Hummel, M., Riess, H., Ogawa, S., Sinn, M., Damm, F.
Publicado 2021

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL

por Rejeski, K., Albanyan, O., Iacoboni, G., Bücklein, V., Blumenberg, V., Penack, O., Bethge, W., Völkl, S., Perez, A., Carpio, C., Schmidt, C., Müller, N., Reid, K., Faramand, R., Davila, M., Bullinger, L., Locke, F., von Bergwelt-Baildon, M., Mackensen, A., Barba, P., Jain, M., Subklewe, M.
Publicado 2022

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

por Dawson, M A, Gudgin, E J, Horton, S J, Giotopoulos, G, Meduri, E, Robson, S, Cannizzaro, E, Osaki, H, Wiese, M, Putwain, S, Fong, C Y, Grove, C, Craig, J, Dittmann, A, Lugo, D, Jeffrey, P, Drewes, G, Lee, K, Bullinger, L, Prinjha, R K, Kouzarides, T, Vassiliou, G S, Huntly, B J P
Publicado 2014

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CH...

por Bücklein, V., Perez, A., Iacoboni, G., Rejeski, K., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F., von Bergwelt, M., Barba, P., Jain, M. D., Subklewe, M.
Publicado 2022

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia

por Krowiorz, K, Ruschmann, J, Lai, C, Ngom, M, Maetzig, T, Martins, V, Scheffold, A, Schneider, E, Pochert, N, Miller, C, Palmqvist, L, Staffas, A, Mulaw, M, Bohl, S R, Buske, C, Heuser, M, Kraus, J, O'Neill, K, Hansen, C L, Petriv, O I, Kestler, H, Döhner, H, Bullinger, L, Döhner, K, Humphries, R K, Rouhi, A, Kuchenbauer, F
Publicado 2016

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial

por Weller, J., Schäfer, N., Schaub, C., Tzaridis, T., Zeyen, T., Schneider, M., Potthoff, A. L., Giordano, F. A., Steinbach, J. P., Zeiner, P. S., Kowalski, T., Sabel, M., Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Tabatabai, G., Ringel, F., Schmidt-Graf, F., Brehmer, S., Tonn, J. C., Bullinger, L., Vajkoczy, P., Glas, M., Vatter, H., Herrlinger, U., Seidel, C.
Publicado 2023

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

por Nagel, Gabriele, Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H. R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., Derigs, H.G., Horst, H. A., Rudolph, C., Heuser, M., Göhring, G., Teleanu, V., Bullinger, L., Thol, F., Gaidzik, V. I., Paschka, P., Döhner, K., Ganser, A., Döhner, Hartmut, Schlenk, R. F.
Publicado 2017

P1439: IMMUNE RESPONSE TO ANTI-SARS-COV-2 MRNA VACCINES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

por Zaleska, J., Kwaśnik, P., Paziewska, M., Purkot, J., Szabelak, A., Jurek, M., Masny, N., Dziatkiewicz, I., Własiuk, P., Skórka, K., Stasiak, G., Pronobis-Szczylik, B., Piebiak, A., Szymczyk, A., Jarosz-Chudzik, K., Bołkun, L., Kozłowska, K., Piszcz, J., Subocz, E., Hałka, J., Bator, M., Kalicińska, E., Wróbel, T., Usnarska-Zubkiewicz, L., Rybka, J., Dereń-Wagemann, I., Szyca-Śmieszniak, M., Dybko, J., Hus, I., Puła, B., Cichocka, E., Rymko, M., Zduńczyk, D., Ziarkiewicz, M., Basak, G., Bullinger, L., Giannopoulos, K.
Publicado 2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

por Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F.
Publicado 2022

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE

por Hernández-Sánchez, A., Villaverde-Ramiro, Á., Martínez Elicegui, J., González, T., Benner, A., Sträng, E., Castellani, G., Heckman, C. A., Versluis, J., Abáigar, M., Sobas, M., Azibeiro, R., Tur, L., Valk, P. J., Metzeler, K. H., Ayala, R., Dall’Olio, D., Tettero, J., Martínez-López, J., Dombret, H., Pratcorona, M., Damm, F., Mills, K. I., Mayer, J., Thiede, C., Voso, M. T., Sanz, G. F., Calado, F., Döhner, K., Gaidzik, V. I., Heuser, M., Haferlach, T., Turki, A. T., Reinhardt, D., Villoria Medina, R., van Speybroeck, M., Schulze-Rath, R., Barbus, M., Butler, J. E., Hernández Rivas, J. M., Huntly, B. J., Ossenkoppele, G. J., Döhner, H., Bullinger, L.
Publicado 2022